Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VDRM...possible stem cell applications.....
The debt situation and the inability of the CEO to provide a clear/coherent picture of exactly what is occurring with the company obviously makes VDRM an extremely high-risk investment. But from a trading perspective, the stock does have its moments in the sunshine.
The press release this past week was an enouraging sign that additional news/activity may be forthcoming. Although most investor attention was directed toward the marijuana (CBD/THC) aspects of the PR, the fact that VDRM appears to have done some possible rebranding of its antibiotic product is something that caught my eye. According to the drug database, the marketing start date for Viabecline was November 8, 2016......
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e53ed13-b71e-494d-b292-5b1cac34689f&type=display
Prior to the recent press release, I accumulated some shares of VDRM because I thought the next push/promotion of the stock might involve the stem cell applications of tetracycline. It has gone largely unnoticed by VDRM investors, but over the last 2-3 months Phillips Company (from which VDRM licenses its tech/products) has been placing a PDF file on its website. The file chronicles the use of TetraStem (beginning July 2016) to treat a human spinal cord injury......
http://www.phillipscompany.4t.com/miranda.pdf
GSAC...finished accumulating position....
ECGI(.015)...ambulatory cardiac monitor.....
ECGI is involved in the cardiac monitoring market, and owns the worldwide marketing rights for NowCardio (ambulatory cardiac monitor). NowCardio has received marketing clearance from Health Canada, and the company was planning to file a 510(k) application sometime in late July/August 2016 for marketing in the United States. ECGI acquired National Cardiac Monitoring Center several months ago, and it will basically become the base for ECGI's operations inside the United States.
ECGI had been basing/churning around the 3-5 cent area, but has moved downward recently. I don't know whether this weakness is an indication that some negative news/development might be approaching, or whether it is simply some overhang working its way out of the stock. Possible negative news might involve an unresolved lawsuit, problems with the July acquisition of National Cardiac Monitoring Center, financing, etc., etc.
It might be a high-risk investment until the situation clarifies itself a little better, but these sub-2 cent prices look extremely attractive for entry/accumulation. IMO, absent anything overly negative coming this way, the stock probably should not be trading this low.
If ECGI has filed its 510(k) application for NowCardio according to its last guidance timetable, the company could receive United States marketing clearance for the device as early as the next month or two. I think once ECGI gets the 510(k) approval, you will probably see a significant increase in the amount of US-based media attention on the product/company.
Financings have been done at significantly higher prices. According to the CEO's August audio interview, the most recently announced financing ($300K) was being used to manufacture 1000 NowCardio devices. It is not widely-known by investors, but during the month of August the company placed job postings for CEO and CFO positions for National Cardiac Monitoring Center. Some of the job requirements for the CFO position included investor relations and SEC filings, so I would assume this person would also take over the CFO duties for ECGI.
Another potential sign that operational/marketing activity for NowCardio and ECGI could be taking a step forward is the job posting that Contex International Technologies made in Canada. Contex is the engineering firm that designed the NowCardio device for ECGI. Based on the job posting, it appears that Contex will be setting up a cardiac monitoring center in Canada (essentially a Canadian version of National Cardiac Monitoring Center)......
GSAC(.0035)...cannabis-sector play......
I accumulated shares of GSAC in the .003-.0035 range last week. GSAC acquired ownership of Mastix Medica about two years ago (and in the process gained exposure to the cannabis sector). GSAC is involved in the research/development, formulation, manufacturing, and marketing of over-the-counter healthcare products (gum, tablets, lozenges, mints, candies, etc.). The company has a patent-pending manufacturing process for incorporating hemp-oil into gums and tablets.
Its a very high-risk investment, but the stock looks relatively attractive given its under-followed nature and the current market interest for sub-penny cannabis plays.
Although it is about a year old, the GSAC Executive Summary from November 2015 provides a nice amount of information about the company and its plans it had heading into year 2016. Included in the summary is info on its cannabis-related activity (products, clinical studies, etc.) and some financial/business information regarding potential products in the pipeline.
Also from the summary.....
$hellKing...CLCL(.0078)...accumulated position.....
IVRO(.02)...distribution network now includes India.....
Fiscal year 2015 financial numbers:
22M shares outstanding
$440K market cap
$995K revenue
$232K net income
$650K cash (2.9+ cents per share)
InVitro International develops and manufactures kits and services that are used to test the corrosivity/irritancy of products on ocular/dermal tissues. The company has been in business for decades and appears (based on its two most recent fiscal years) to be at a possible positive turning point in its business activities.
Although IVRO has not yet updated its website to reflect the following, it is interesting to note that IVRO appears to have recently entered into a distribution agreement with a company in India. InVitro's logo and website link can be found on the website of Krishgen Biosystems India. Krishgen has a scrolling news section on the left side of its website. The July 21, 2016 item mentions IVRO and its two products.......
ECGI(.058)...acquisition, medical device clearances.....
ECGI's acquisition of a US-based data monitoring center is expected to occur this Friday (as per the 8-K filing).
In addition to the marketing clearance from Health Canada that the company received for its NowCardio product, ECGI is expecting to receive at least two other marketing clearances before the end of 2016 (United States and Europe).......
CLCL...increased my position....
I accumulated more shares of CLCL this week at the sub-penny level. All things considered, the timing now for entry/accumulation of CLCL probably has never looked more attractive in the years that I have followed the stock.
It is an encouraging sign that both websites CEO Norman Kaplan mentioned in his email to adijas are now offline (see post below). Last week the company took its main website (calcol.com) offline.....
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123541465
ECGI...Health Canada clearance, FDA timeline.....
adijas...CLCL...increased my position.....
Nice financing, corporate development.....
Medical Device Daily...April 19, 2016 article.....
Filing delinquency...reply to private message.....
To the person who sent me a private message regarding VODG's SEC filing delinquency.....
Until VODG actually becomes current on its SEC filings, I think it is only prudent to be at least somewhat concerned about the potential for suspension/revocation of the stock. My guess is that VODG will be able to avoid the SEC taking action on the stock, but that is purely a guess on my part.
Over the last few years the SEC seems to have become increasingly erratic/inconsistent in its approach to handling filing delinquency situations, so anytime you have a stock fall into a delinquent status for an extended period of time (like VODG) it is wise to be somewhat cautious.
That inconsistency by the SEC has made it much more difficult for retail investors in shells and many active/operating small cap companies. There are a number of what I would consider to be extremely attractive shells or operating companies out there, but the SEC's "preemptive strike" policy it enacted a few years ago and its inconsistent/random enforcement of filing deliquencies increases the risk level in these investments.
A few years ago the SEC revoked a perfectly fine 15-12G shell, forcing the attorney who controlled the shell to liquidate the shell and distribute the cash to the shareholders. Meanwhile the SEC allows another shell to continue trading (even though it is now about 24 years delinquent on its SEC filings). I know of one shell a few years ago that was suspended/revoked even though the investment firm that controlled the shell was in fact getting the filings updated. So the firm lost all the money it spent on acquiring the shell, plus any money it spent on the filings. That is the type of inconsistency that has a lot of investors increasingly frustrated.
I think most investors would be served better if the SEC practiced what it preaches: full disclosure. I don't think it is too much to ask that the SEC provide the public with timely information on any contact/demands it has made with any companies it may be targetting for suspension/revocation. It would be incredibly helpful (and potentially very profitable) if you knew whether or not a specific delinquent company or shell was in any significant or imminent danger from the SEC. For example, the delinquent biotech/pharma VPRO had a monster move from its low in the last year or so for those investors who correctly guessed/gambled that the SEC would not suspend/revoke the stock in the near term.
Allowing the average investor an opportunity to make a better buy/sell decision before actually suspending/revoking the stock doesn't seem like an unreasonable request.
Health Canada application, MedPac equity position.....
If the guidance in the quarterly report filed two weeks ago (April 15) is accurate, ECGI should be submitting the NowCardio application to Health Canada sometime within the next two months. Generally speaking, medical device applications in Canada usually get processed quicker than in the United States (weeks/months versus months)......
ECGI...increased my position.....
I increased my ECGI position last week. The risk/reward around this 3-cent area, and the timing for entry/accumulation, looks reasonably interesting right now. I would assume the first of the marketing approvals (Health Canada) is probably getting fairly close. Depending on how much lasting damage was done to the stock during the Fall/Winter, my guess is there will be some potential for pretty nice tradeable moves/spikes in the share price over the next 6-months or so.
Last week, the company (and/or the investors relations firm the company had hired last year) started making some updates to the website. For a better part of the last 6 months or so, the website had basically been neglected. Interesting to note that additions/changes have been made to the management team and the advisory board.......
http://www.eventcardiogroup.com/
The $1.08M financing package (6.4 cents per share, and 15-cent warrants) in February was an important and very encouraging development, especially since the Life Medical dispute has not been resolved yet. It is pretty clear that those investors believe the company will remain a viable business/investment, and it is also an extremely high vote of confidence that ECGI will successfully obtain marketing approvals for NowCardio in markets outside Canada. The way the licensing agreement for NowCardio is currently set up, ECGI only receives significant fundamental benefits from its activity in the non-Canada markets.
Also worth noting (according to the financing agreement 8-K): The company consolidated the bulk of its related party debt into a promissory note convertible at CAN$.0873 (which is usually around 6-7 US cents, depending on currency rates).
March 1 press release is interesting/encouraging.....
dickmilde...regarding IVRO......
IVRO(.0141)...revenue/income/cash at 18-year highs.....
22M shares outstanding
$310K market cap
$650K cash
FY 2015 (September 30) net income around .01/share
Does not file with the SEC or OTC Markets
IVRO develops/markets kits and laboratory services for the testing of ocular and dermal irritancy/toxicity of materials.
The revenue, net income and cash levels reported in IVRO's fiscal year 2015 financial results press release represent 18-year highs for the company.....
GNPG...anticipating corporate developments.....
I'm semi-expecting to see an increase in corporate activity/developments over the next few months. The sale of GNPG's XenTx Lubricants subsidiary could occur sometime in March. Once that is complete I would assume most of the company focus will turn to the remaining subsidiaries.
Over the last month or so, GNPG has made changes to its authorized/preferred share structures, did some slight redesign work on its website, and a new Treasurer/Secretary/Director (Don Burton) was appointed.
It will be interesting to see if any upcoming announcements/developments create some movement/push on the stock in the coming weeks/months.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120645884
GNPG(.008)...expected sale of a subsidiary....
It has gone largely unnoticed, but in GNPG's February 17 financial results press release the company stated it may announce the sale of its XenTx Lubricants subsidiary sometime in the next 6 weeks. The share price seems to have been firming up a little in the last few weeks, so it is possible this anticipated sale might cause a pop in the share price. GNPG's current fiscal year ends on March 31......
IVRO(.015)...2015 financials, future looks encouraging....
22M shares outstanding
$330K market cap
$995K revenue
$650K cash (2.9+ cents per share)
I picked up some shares of IVRO today. The fiscal year 2015 financial results press release last week shows nice improvements in the areas of revenue, earnings and cash. It is possible this could represent a significant turning point in the company's history, as the CEO's statements in the press release seem upbeat/encouraging......
ASKH(.026)...shell, 11.1M outstanding.....
I'm holding a position in this shell. I think the chances of seeing some type of merger/acquisition activity and/or some type of push/promotion on the stock this calendar year might be relatively decent.
The share structure looks to be reasonably tight right now, with 11.1M outstanding and a float under 3M. The CEO purchased control of the shell in late 2013 and owns 8.16M shares at a cost basis of about 4.3 cents/shr ($350K). Any shares that changed hands during the promotional activity that occurred in the year following his purchase of the shell appears to have come from the existing float, since his share ownership number/percentage has not changed.
During the second half of 2015, ASKH hired a financial/investment consulting firm, registered a new website and regained its SEC filing compliance. That consulting firm is expected to receive about $23K worth of free-trading shares, so I am anticipating there will be a noticeable increase in volume activity at some point.
Primary focus appears to be on acquisition/merger and business activities with companies based in New Zealand and China. The website for the China-based textile company (Jiangsu Ziyang Holiday Bedroom Articles Co. Ltd.) that is currently featured prominently on the ASKH website can be found below. Jiangsu Ziyang appears to have a pretty well-established textile brand. If I recall correctly, the CEO/company was mentioned in a news article last summer and had secured a $2.5 million government loan. The growth plans for 2015-2017 that were put up on company's website back in 2014 included increased expansion into RT-Mart, Carrefour, and Walmart stores.
http://nantongglobalventures.com/
http://www.ziyangjiafang.com/home.html
ECGI...reply to private message.....
To the person who inquired about my current thoughts on ECGI.....
I still hold my position in ECGI, as I think the possibility of substantial upside from this price range still exists. But obviously the risk factor has significantly increased as a result of the disputes between ECGI, Life Medical and Medpac Asia Pacific.
The negative developments surrounding the BreastCare DTS division of the company over the last month or so have been extremely disappointing, to say the least. Unless there is a very reasonable/amicable resolution to all of the disputes here, the entire BreastCare DTS part of the business could end up being an extremely expensive waste of ECGI's corporate time/resources.
In my opinion, most of the current problems/mess could have been avoided if CEO John Bentivoglio and ECGI's legal counsel would have done a better job of protecting the company when the licensing agreement for BreastCare DTS was crafted/signed. At a minimum, there should have been clauses placed in that agreement that would have pushed back the timeline on any financial obligations until after the full-scale production/manufacturing line for BreastCare DTS was actually completed.
The latest 8-K (12/17/2015) about Medpac withdrawing its default notice is a potentially encouraging sign. It would have been helpful if ECGI could have provided a little more clarification on whether the withdrawl means the two parties have completely resolved their particular dispute, or whether the disagreement still exists and Medpac is just temporarily withdrawing its default/demand......
ASKH...symbol appears on website.....
Interesting to note that within the last few days the ASKH stock symbol has been added to the front page of the Nantong Global Ventures website. The symbol (linked to the ASKH OTC Markets profile) also now appears as a separate item on the menu bar.
This is the first time the stock symbol has appeared on the front page since the website was created in August......
http://nantongglobalventures.com/
BNXR(.0075)...possible quasi-shell.....
24.63M shares outstanding
21.8M float
$185K market cap
Accumulated some shares of BNXR over the last couple of weeks. The price range around the .004-.007 area seems like a reasonable area for entry/accumulation, IMO.
Jeffrey Beckett (an activist shareholder, owns 2.83M shares of BNXR) filed a lawsuit in 2013 against previous management, accusing the parties of mismanagement and personal enrichment. As settlement of the lawsuit, Beckett has basically taken control of the company in late June 2015. All previous management/directors have resigned, and Beckett is now the Chairman/President.
I don't know if Beckett intends to continue BNXR's current area of operations (oil & gas), or if he is planning to turn BNXR into a shell and seek other opportunities for the company. Hence the reason why I refer to BNXR as a "quasi-shell".
I'm fully anticipating/expecting the possibility of seeing additional relatively intense periods of selling pressure, because there are a number of risk factors here: for example, high float percentage, possibly disgruntled/vindicative shareholders as a result of the lawsuit, possible debt/expenses related to continued operations or converting BNXR into a shell, etc.
But, all things considered, this looks like a potentially interesting situation. Beckett's cost basis on the shares he purchased is over $270,000 (around 9.5+ cents per share). I'm not 100% certain, but I think the "Jeffrey Beckett" that now controls this company is the founder of Retailvelocity.com and has significant connections/relationships with people in the areas of software, sales, marketing,etc.......
https://www.linkedin.com/in/jeff-beckett-5867348b
ASKH...consultant agreement.....
Interesting to note that ASKH entered into a consulting agreement with an investment firm in June 2015 (see below). Based on the recently-filed periodic reports, this appears to be the first outside consultant the new CEO has employed since he purchased control of the shell in late 2013.
Whether the consultant can help complete any financing or merger/acquisition transactions for ASKH remains to be seen, but at a minimum it is a noticeable and more aggressive/proactive change in approach by the company/CEO.
Terms/conditions of the potential share issuance to the consultant have not been disclosed, so that is an additional risk factor that should be considered here. I'm still holding my full position and semi-expecting to see some higher-volume activity and a pretty significant move in the share price sometime between now and early-mid 2016.
JonesBur...reverse mergers, VODG.....
VODG...things might get interesting soon.....
I picked up some more shares under the 4-cent level in the last week or two for trading purposes (looking for a possible move into the 15-20 cent range for those particular shares). Risk/reward around that 4-cent area looked reasonably attractive to me considering there should be some increased corporate activity over the remainder of calendar 2015 and into early-mid 2016.
Clearance/approval of the clinical trial(s) should be getting closer. My guess/hunch is that information surrounding the clinical trial approval (possible collaborations/partnerships/funding) might trigger some positive movement in the share price. The recent expansion of VODG's bioanalytical services beyond primarily immune-related conditions is also rather interesting.
With VODG entering into the consultant agreement with C Brook Ventures, I think there is a pretty strong possibility of seeing some corporate activity in the areas of financing or merger/acquisition here in fiscal 2016 (which began about a week ago). If Sean Kenlon wants to maximize his firm's financial return on its consultant agreement with VODG (by getting access to the warrant package, and/or any to-be-negotiated deal or performance bonus), he needs to find a financing or strategic merger/acquisition that is acceptable to Musick/VODG.
The consultant agreement (as per the details in the 8-K) was quite interesting because it specifically included the possibility of using VODG for a reverse merger (presumably transferring the current assets/liabilities out of VODG and using the corporate shell to bring in a new company). That would suggest to me that Musick and C Brook Ventures may have at the very least had some initial/premilimary discussions about such a possibility.
Given the tone/statements of the recent shareholder/update letter it would appear more likely now that VODG intends to maintain its current primary operations and continue forward as a public company and pursue strategic/complementary mergers and acquisitions.
Sean Kenlon LinkedIn profile....
https://www.linkedin.com/profile/view?id=AAEAAAQSMDIBe3GGls6xsKJg2xIGJPeK-v9QZKw&authType=name&authToken=n47J&trk=prof-sb-browse_map-name
ASKH...reinstatement is an encouraging sign......
In early August the company stated on the new corporate website its intentions of getting its SEC filings updated. The reinstatement and address change on its Florida filings about a month or so later is an encouraging sign that things may be progressing toward a fully-updated status.
Depending on the conditions I mentioned in the post below, I think there is a reasonably decent chance of seeing a move somewhere into the 10-30 cent area.......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116934362
MRDH's ACO performance....2013 vs 2014......
About a month ago CMS (Centers for Medicare and Medicaid Services) released the 2014 performance figures for the nation's Accountable Care Organizations. This is a very difficult/complicated business and most of the organizations do not earn any performance bonuses, so it is completely understandable and expected that Meridian Health Systems ACO would have similiar struggles.
However, it is a little bit interesting to note that MRDH's ACO showed some fairly significant overall improvements in 2014. Both the financial and quality measurements were noticeably improved. The short-term trend of the numbers looks somewhat encouraging.
2013: http://www.pulsepilot.com/directory/Meridian-Health-Systems-ACO-Corporation/2013#performance
2014: http://www.pulsepilot.com/directory/Meridian-Health-Systems-ACO-Corporation#performance
http://cdn.kaiserhealthnews.org/attachments/AccountableCareOrganizationperformance2014.pdf
ECGI(.151)...NowCardio introduction expected in Q4.....
ASKH(.0345)...shell, accumulated a position.....
This is an extremely high-risk investment, primarily because of the deliquency in the company's SEC filings (late with its 2014 10-K and the first two quarterly reports for 2015).
I finished accumulating a position in the ASKH shell. Last reported share structure was 11.1M shares outstanding, with a float under 3M. Depending on whether there has been any significant/negative changes in the company share structure or debt since the last report, the valuation of this shell around the 1-3 cent area looks reasonably attractive to me for entry/accumulation (under $400K market cap).
The current CEO purchased control of ASKH in late 2013. In early 2014 a new business direction/focus was announced (strategic acquisitions and business activities in Asia and New Zealand), and there was some promotional activity of the stock at various times throughout the year. As far as I am aware, none of the potential acquisitions were completed, so ASKH should still be a relatively clean shell (depending on the conditional statements I made above, of course).
It has gone largely unnoticed by investors, but the CEO registered a new website for the company in early August 2015. It appears that the company has refocused and is preparing another relaunch of the business plan. A new acquisition target (a textile company in China) is prominently featured on the new site.
The press release on the website mentions the possibility of acquiring dairy operations in New Zealand, and also reaffirms ASKH's continued interest in the industrial hemp market in Asia and New Zealand. It is also interesting to note the PR states that the company intends to update its SEC filings.......
Nevada filings updated last week.....
db7...Pete Shuster's resignation......
aboveandbeyond...next few months/quarters......
JonesBur...VODG's SEC requirements.....
NowCardio status update...FDA/Health Canada Testing....
Very interesting to note that the ECGI website has been redesigned/updated within the last day or two. A new (March 24) status update file for the NowCardio project has been placed on the site.
It appears things might get a bit more interesting regarding NowCardio here in the second half of 2015, if the information in this file remains reasonably accurate. FDA/Health Canada testing and application is in progress (page 3). According to the certification roadmap/timeline in this particular file, Health Canada approval and FDA clearance could occur anytime between now and August/September 2015 (page 4)......
http://www.eventcardiogroup.com/wp-content/uploads/2015/04/CONTEX-NowCardio-Status-Update-March-24-2015.pdf
Also, from my post on another message board, here is some information about what appears to be a recent, undisclosed agreement for distribution of BreastCare DTS in Latin America......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115580913
ECGI(.07)...Latin America distribution, Frost & Sullivan.....
ECGI(.07)...BreastCare DTS business plan update.....
I continue to hold my position in ECGI, and still expect to see prices well above the 20-cent level at some point. IMO, the 5-10 cent area looks reasonably attractive for entry/accumulation of both core and trading positions. If the company successfully executes on its current business plan, I am anticipating significant tradeable opportunities in the ECGI stock over the next 12+ months.
This week the company started putting updated business/financial presentations on the investors section of its website. It appears much of the final packaging design for the NowCardio system/product has been completed. The target time frame for the ramp-up of the BreastCare DTS business/product appears to be the first quarter of 2016. The anticipated blanket purchase orders mentioned in the business plan would represent annual revenues exceeding $20M.
Some items of interest from the May 2015 BreastCare DTS business plan.....
1)
MRDH...website items, CEO Twitter account.....
Increased my MRDH position in the last couple of weeks by picking up some shares under the 2-cent level. There has been some website activity related to MRDH in 2015, and something somewhat interesting showed up in the "portfolio" section within the last couple of days or so.
In January, CEO Anthony Dike registered another website for the ACO business. The 2015 Participating Provider list was also placed on the website in January, and it shows a significant increase in the total number of physicians operating under the MRDH ACO.......
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111235072
http://www.meho.com/mhsaco/Providerlist2015.pdf
http://www.meho.com/mhsaco/Providerlist2014.pdf
I noticed that a few weeks ago, MRDH placed a third-party health information search engine on its website.
The company does a terrible job of keeping its website completely updated/functional, so it is always difficult to determine what items on its site are still relevant. But I found it rather interesting that one of the subsidiary names that started showing up in the portfolio section of the website within the last week is "Meridian Energy Corporation", which is a name that hasn't appeared on the website in a significant number of years.
At first I thought maybe this was just nothing more than a website glitch, but the description of the subsidiary is definitely different from the past description. The current Meridian Energy is apparently focused on wireless monitoring/surveillance of energy properties and field operations. And perhaps more interesting is the fact that the document properties of the PDF file associated with this subsidiary, show that Anthony Dike created the file on May 28, 2015......
http://www.meho.com/portfolio_me.htm
http://meho.com/MeridianEnergy.pdf
Also somewhat interesting to note that the CEO opened up a Twitter account in April 2015. He has used that account primarily to advertise/promote two crowdfunding campaigns he started this year involving two technologies his privately-held cardiovascular medical device/treatment company licensed from NASA (Microwave Wound Welding, and Endothelium Preserving Microwave Treatment for Atherosclerosis).
It would probably be unlikely those campaigns would actually raise the targeted money since he does not appear to be offering equity/financial participation in the projects. Both of those technologies could have significant commercial appeal, and would represent a pretty interesting wildcard play if he were to sublicense that tech to a MRDH subsidiary or a company that MRDH might have an equity position in.
https://twitter.com/acdike1